medigraphic.com
ISSN 2078-7170 (Electronic)

2016, Number 3

<< Back Next >>

CorSalud 2016; 8 (3)

Short-coupled premature ventricular contractions triggering malignant arrhythmias

Dorantes SM, Ponce PE, Falcón RR

Language: Spanish
References: 31
Page: 144-152
PDF size: 913.48 Kb.


ABSTRACT

Introduction: Some malignant ventricular arrhythmias are triggered by shortcoupled ventricular premature contractions.
Objective: To characterize patients with syncopal events or sudden death due to malignant ventricular arrhythmias triggered by this type of premature complexes.
Method: There were studied 29 subjects, 16 women and 13 men, with an average age of 38, with and without structural heart disease, whether they received or not antiarrhythmic drugs, with events of sudden or syncopal death from malignant arrhythmias triggered by short-coupled ventricular premature contractions. Clinical history, electrical sequences, echocardiogram, telemetry, ergometry, coronary angiography, pharmacological tests, and programmed electrical stimulation were evaluated, if necessary.
Results: The most common presentation of sudden death was of 89.6%. Ventricular fibrillation was the most frequent arrhythmia (20 events), followed by helical ventricular tachycardia and others. The coupling was ultra-short in 59.4% and short in 40.6%. In 61.5%, sudden death events were triggered by ultra-short premature ventricular complexes, after that, they are considered high risk. The treatments were the cardioverter-defibrillator, antiarrhythmic drugs or their suppression, and others. There were two deaths, both without cardioverter.
Conclusions: Short-coupled ventricular premature contractions are premonitory electrical markers and trigger of malignant ventricular arrhythmias and sudden death in patients with and without structural heart disease. The lower the degree of coupling, the greater the frequency of malignant arrhythmias and sudden death. This is an important factor for the risk stratification of premature ventricular complexes, but it is not the only one.


REFERENCES

  1. Katritsis DG, Josephson ME. Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? Europace. 2012;14:787-94.

  2. Callans DJ, Josephson ME. Management of ven-tricular arrhythmias: an historical perspective. En: Contemporary Cardiology: Management of cardiac arrhythmias. 2011. p. 3-16.

  3. Callans DJ, Epstein AE. Reflections on the lowly PVC. Heart Rhythm. 2015;12:714-5.

  4. Lee YH, Zhong L, Roger VL, Asirvatham SJ, Shen WK, Slusser JP, et al. Frequency, origin, and out-come of ventricular premature complexes in pa-tients with or without heart diseases. Am J Car-diol. 2014;114:1373-8.

  5. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encai-nide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-12.

  6. Haïssaguerre M, Shoda M, Jaïs P, Nogami A, Shah DC, Kautzner J, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962-7.

  7. Marai I, Gepstein L, Boulos M, Suleiman M. Abla-tion of idiopathic ventricular fibrillation triggered by ventricular premature beat originating from myocardium of right ventricle: Case report. J Car-diol Cases. 2014;9:109-12.

  8. Hayama Y, Kaitani K, Onishi N, Tamaki Y, Miyake M, Kondo H, et al. Ablation of idiopathic ventric-ular fibrillation targeting short coupled ventric-ular premature contractions originating from a right ventricular papillary muscle. J Cardiol Cases. 2014;9:113-6.

  9. Lindsay BD. Eliminating triggers of ventricular fibrillation: the past, present, and future. J Am Coll Cardiol. 2009;54:529-30.

  10. 10.Nogami A. Purkinje-related arrhythmias Part II: Polymorphic ventricular tachycardia and ventric-ular fibrillation. Pacing Clin Electrophysiol. 2011; 34:1034-49.

  11. 11.Chinushi M, Iijima K, Sato A, Furushima H. Short-coupling premature ventricular complexes from the left ventricle triggered isoprotenerol-resistant electrical storm in a patient with Brugada syn-drome. Heart Rhythm. 2013;10:916-20.

  12. 12.Laurent G, Saal S, Amarouch MY, Béziau DM, Marsman RF, Faivre L, et al. Multifocal ectopic Purkinje-related premature contractions. A new SCN5A-related cardiac channelopathy. J Am Coll Cardiol. 2012;60:144-56.

  13. 13.Viskin S, Rosso R, Rogowski O, Belhassen B. The “short-coupled” variant of right ventricular out-flow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia. J Cardiovasc Electrophysiol. 2005;16:912-6.

  14. 14.Sullivan RM, Olshansky B. Treatment of PVCs post-myocardial infarction: will we get fooled again. Heart Rhythm. 2009;6:1550-1.

  15. 15.Sánchez Muñoz JJ, García-Alberola A, Mártinez-Sánchez J, Peñafiel-Verdú P, Caro-Mártinez C, Manzano-Fernández S, et al. Extrasistolia ventric-ular desencadenante de la fibrilación ventricular. Rev Esp Cardiol. 2010;63:798-801.

  16. 16.Viskin S. Idiopathic ventricular fibrillation “Le syndrome d’Haïssaguerre” and the fear of J waves. J Am Coll Cardiol. 2009;53:620-2.

  17. 17.Kondo H, Shinohara T, Takahashi N. A case of short-coupled premature ventricular beat-in-duced ventricular fibrillation with early repolar-ization in the inferolateral leads. J Arrhythmia. 2015;31:60-3.

  18. 18.Dorantes M. Algo de historia. Proarritmia. Rev Cubana Cardiol Cir Cardiovasc [Internet]. 2012 [citado 14 Jul 2016];18:228-31. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/326/316

  19. 19.Scheinman MM. Role of the His-Purkinje system in the genesis of cardiac arrhythmia. Heart Rhythm. 2009;6:1050-8.

  20. Ideker RE, Kong W, Pogwizd S. Purkinje fibers and arrhythmias. Pacing Clin Electrophysiol. 2009;32:283-5.

  21. 21.Baher AA, Uy M, Xie F, Garfinkel A, Qu Z, Weiss JN. Bidirectional ventricular tachycardia: ping pong in the His-Purkinje system. Heart Rhythm. 2011;8:599-605.

  22. 22.Rosenheck S. Arrhythmogenicity of the Purkinje system: a new step toward understanding ventric-ular fibrillation. Heart Rhythm. 2009;6:1790-1.

  23. 23.López Delgado A, Dorantes Sánchez M. Fibrila-ción ventricular idiopática. Rev Cubana Cardiol Cir Cardiovasc [Internet]. 2013 [citado 4 Jul 2016]; 19:5-12. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/310/526

  24. 24.Dorantes M. Apunte histórico sobre la quinidina. CorSalud [Internet]. 2013 [citado 20 Jul 2016];5: 361-5. Disponible en: http://www.sld.cu/galerias/pdf/sitios/cardiologia/corsalud_quinidina.pdf

  25. 25.Belhassen B. Is quinidine the ideal drug for Bru-gada syndrome? Heart Rhythm. 2012;9:2001-2.

  26. 26.Vardas PE, Kanoupakis EM. Old drugs never die; they just fade away. Heart Rhythm. 2010;7:864.

  27. 27.Viskin S, Antzelevitch C, Márquez MF, Belhassen B. Quinidine: a valuable medication joins the list of ‘endangered species’. Europace. 2007;9:1105-6.

  28. 28.Viskin S, Wilde AA, Tan HL, Antzelevitch C, Shi-mizu W, Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm. 2009;6:401-4.

  29. 29.Viskin S, Belhassen B, Wilde AA. Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm. 2010;7:863.

  30. 30.Márquez MF, Bonny A, Hernández-Castillo E, De Sisti A, Gómez-Flores J, Nava S, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an im-plantable cardioverter-defibrilator: a case series and literature review. Heart Rhythm. 2012;9:1995-2000.

  31. 31.Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009;122:317-21.




2020     |     www.medigraphic.com